Prenatal exposure to hot, humid conditions was associated with significantly reduced child growth, with effects far greater than heat alone. Extreme heat is a well-recognized health risk during ...

Check out the top 5 pharmacology articles of 2025. The increasing availability of at-home infant cardiorespiratory monitoring devices has raised important questions for pediatric practice regarding ...

Join us for a recap of some of our top dermatology puzzler cases from 2025. A 21-year-old primigravida woman presented to the hospital in preterm labor, with an otherwise uneventful pregnancy except ...

“We started out 2025 with an environment that was rife with myths and disinformation," said Robert H. Hopkins, Jr., MD, in this year-end recap of 2025 and the pediatric vaccine landscape. Pediatric ...

Approval of the expanded indication fullfilled all post-marketing requirements outlined in the original approval letter. On December 23, 2025, the FDA approved an expanded indication for furosemide ...

Strategic Alliance Partnership | Contemporary Pediatrics connects pediatricians with peer-reviewed articles, guideline updates, and practice strategies for real-world clinical application.

"For those not receiving the HBV birth dose, it is suggested that the initial dose is administered no earlier than 2 months of age," reads part of vote 1. The Centers for Disease Control and ...

Higher maternal vitamin D levels in pregnancy were associated with reduced odds of early childhood caries and lower dmft scores in offspring. Higher maternal 25-hydroxyvitamin D levels were ...

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from November 2025. Another month has come and gone, and with it, several FDA approvals and regulatory ...

Waskyra becomes the first FDA-approved gene therapy for Wiskott-Aldrich syndrome, offering hope to patients with this rare immunodeficiency. On December 9, 2025, the FDA approved Waskyra ...

“Having a drug that [patients] can be confident in that will be highly effective as well as well tolerated is a great advantage," said Edward Hook, MD. The FDA recently approved Nuzolvence ...

Following an updated policy from the American Academy of Child and Adolescent Psychiatry, Joshua Feder, MD, explains why providers should present DRBIs and NDBIs as options for autism care.